MicroRNA-206 serves as a tumor suppressor in pediatric acute myeloid leukemia by targeting Cyclin D1

Liu, Hong; Wu, Haiying; Qin, Xiangzheng

doi:10.1016/j.prp.2019.152554

“…Therefore, it is reasonable to suggest that hsa-mir-206 can act as a key site in regulating the development of AML by mediating the expression of NFAT5. Moreover, it has been reported that low expression of hsa-mir-206 is closely associated with the poor prognosis of pediatric AML patients [26]. This is consistent with our nding that the downregulation of hsa-mir-206 predicts poor prognosis in AML.…”

Section: Discussionsupporting

confidence: 92%

Identification of prognostic biomarkers and potential regulatory axes for acute myeloid leukemia based on a competitive endogenous RNA network

Li

¹

,

Chen

²

,

Chen

³

et al. 2021

Preprint

2

0

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is a common heterogeneous hematological malignancy with unclear pathogenesis and high mortality. Non-coding RNAs have recently received extensive attention. This study explored the potential mechanisms of interaction during the development of AML by analyzing a competitive endogenous RNA (ceRNA) network. Methods To obtain differentially expressed genes (DEGs), the transcripts and clinical AML data were downloaded from The Cancer Genome Atlas (TCGA) database. Bioinformatic analysis was used to predict the function annotation and RNA interaction. The data were used to construct a ceRNA regulatory network and survival analysis was used to discover key genes and predict potential regulatory axes. Quantitative Real-time PCR (qRT-PCR) was used to detect DEGs in HL-60 and THP-1 cell lines to verify the prediction. Results A ceRNA regulatory AML network with 164 lncRNA-miRNA-mRNA regulatory axes was constructed and visualized by Cytoscape software. Six lncRNAs were screened as potential prognostic factors for AML by survival analysis. Additionally, hsa-mir-206 and NFAT5 were discovered as key nodes in the ceRNA network. A CTB-193M12.1/hsa-mir-206/NFAT5 axis that was consistent with the ceRNA theory was identified. The qRT-PCR result showed that, compared with the normal control group, the expression of hsa-mir-206 in HL-60 and THP-1 cells was significantly decreased, while that of NFAT5 was moderately increased. Conclusions Therefore, the obtained ceRNA network and the CTB-193M12.1/hsa-mir-206/NFAT5 axis here may provide new view for exploring the pathogenic mechanisms of AML. NFAT5 and hsa-mir-206 were novel clinical predictors that may become key genes in AML.

show abstract

“…These had to be extracted from the survival curve in the remaining eight articles. Twelve different cancers were assessed in this study, including rhabdomyosarcomas (RMS) [ 32 ], malignant astrocytomas [ 13 ], melanoma [ 14 ], GC [ 15 , 18 , 22 ], CRC [ 16 , 19 ], osteosarcoma [ 17 ], RCC [ 26 , 27 , 29 ], AML [ 24 ], CC [20, 21, 23, 30], breast cancer (BC) [ 31 ], NSCLC [ 25 ], and ESCC [ 28 ]. The mean NOS scores of the included studies were 6.5.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis

Liu

¹

,

Zheng

²

,

Peng

³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

It has been reported that microRNA-206(miR-206) plays an important role in cancers and could be used as a prognostic biomarker. However, the results are controversial. Therefore, we summarize all available evidence and present a meta-analysis to estimate the prognostic value of miR-206 in various cancers. The relevant studies were collected by searching PubMed, EMBASE, and Web of Science databases until August 21, 2020. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the association between miR-206 and survival results and clinicopathologic features. Sources of heterogeneity were investigated by subgroup analysis and sensitivity analysis. Publication bias was evaluated using Egger’s test. Twenty articles involving 2095 patients were included in the meta-analysis. The pooled HR showed that low miR-206 expression was significantly associated with unfavourable overall survival (OS) ( HR = 2.03 , 95 CI%: 1.53-2.70, P < 0.01 ). In addition, we found that low miR-206 expression predicted significantly negative association with tumor stage (III-IV VS. I-II) ( OR = 4.20 , 95% CI: 2.17-8.13, P < 0.01 ), lymph node status (yes VS. no) ( OR = 3.58 , 95%: 1.51-8.44, P = 0.004 ), distant metastasis (yes VS. no) ( OR = 3.19 , 95%: 1.07-9.50, P = 0.038 ), and invasion depth ( T 3 + T 4 vs. T 2 + T 1 ) ( OR = 2.43 , 95%: 1.70-3.49, P < 0.01 ). miR-206 can be used as an effective prognostic indicator in various cancers. Further investigations are warranted to validate the present results.

show abstract

“…Based on these findings, it can be assumed that ZNF667-AS1 could have an oncogenic role in AML. It was found that ZNF667-AS1 acts as a molecular sponge for miR-206 with known tumorsuppressor function in pediatric AML patients [154]. Down-regulation of ZNF667-AS1 reduces proliferation and invasion of leukemic cells, acting through miR-206/A-kinase anchoring protein 13 (AKAP13) axis, or miR-206/Cyclin D1 axis [153,154].…”

Section: Lncrna Znf667-as1mentioning

confidence: 99%

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia

Gašić

¹

,

Karan-Djurašević

²

,

Pavlovic

³

et al. 2022

Life

View full text Add to dashboard Cite

Leukemia is a heterogenous group of hematological malignancies categorized in four main types (acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Several cytogenetic and molecular markers have become a part of routine analysis for leukemia patients. These markers have been used in diagnosis, risk-stratification and targeted therapy application. Recent studies have indicated that numerous regulatory RNAs, such as long non-coding RNAs (lncRNAs), have a role in tumor initiation and progression. When it comes to leukemia, data for lncRNA involvement in its etiology, progression, diagnosis, treatment and prognosis is limited. The aim of this review is to summarize research data on lncRNAs in different types of leukemia, on their expression pattern, their role in leukemic transformation and disease progression. The usefulness of this information in the clinical setting, i.e., for diagnostic and prognostic purposes, will be emphasized. Finally, how particular lncRNAs could be used as potential targets for the application of targeted therapy will be considered.

show abstract

MicroRNA-206 serves as a tumor suppressor in pediatric acute myeloid leukemia by targeting Cyclin D1

Cited by 12 publications

References 13 publications

Identification of prognostic biomarkers and potential regulatory axes for acute myeloid leukemia based on a competitive endogenous RNA network

Identification of prognostic biomarkers and potential regulatory axes for acute myeloid leukemia based on a competitive endogenous RNA network

Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia

Contact Info

Product

Resources

About